236 related articles for article (PubMed ID: 32461544)
21. Long-term follow-up of remission duration, mortality, and second malignancies in hairy cell leukemia patients treated with pentostatin.
Flinn IW; Kopecky KJ; Foucar MK; Head D; Bennett JM; Hutchison R; Corbett W; Cassileth P; Habermann T; Golomb H; Rai K; Eisenhauer E; Appelbaum F; Cheson B; Grever MR
Blood; 2000 Nov; 96(9):2981-6. PubMed ID: 11049974
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of pentostatin compared with cladribine in the management of hairy cell leukemia in the United Kingdom.
Guest JF; Smith H; Sladkevicius E; Jackson G
Clin Ther; 2009; 31 Pt 2():2398-415. PubMed ID: 20110049
[TBL] [Abstract][Full Text] [Related]
23. Real-world data on diagnostics, treatment and outcomes of patients with hairy cell leukemia: The HCL-CLLEAR study.
Panovská A; Žák P; Jurková T; Arpáš T; Brychtová Y; Vašíková A; Hrabčáková V; Prchlíková A; Filipová M; Doubek M
Hematol Oncol; 2024 May; 42(3):e3280. PubMed ID: 38741354
[TBL] [Abstract][Full Text] [Related]
24. Hairy cell leukemia treated initially with purine analogs: a retrospective study of 107 patients from the Spanish Cooperative Group on Chronic Lymphocytic Leukemia (GELLC).
López Rubio M; Da Silva C; Loscertales J; Seri C; Baltasar P; Colado E; Pérez Fernández I; Osma M; Gomis F; González M; Jarque I; Vargas M; Monzó E; Monteagudo D; Orts MI; Pardal E; Carbonell F; Perez Calvo C; Garcia-Marco JA
Leuk Lymphoma; 2014 May; 55(5):1007-12. PubMed ID: 23885799
[TBL] [Abstract][Full Text] [Related]
25. Five years follow-up after 2-chloro deoxyadenosine treatment in thirty patients with hairy cell leukemia: evaluation of minimal residual disease and CD4+ lymphocytopenia after treatment.
Bastie JN; Cazals-Hatem D; Daniel MT; D'Agay MF; Rabian C; Glaisner S; Noel-Walter MP; Dabout D; Flandrin G; Dombret H; Poisson D; Degos L; Castaigne S
Leuk Lymphoma; 1999 Nov; 35(5-6):555-65. PubMed ID: 10609793
[TBL] [Abstract][Full Text] [Related]
26. Prospective long-term follow-up after first-line subcutaneous cladribine in hairy cell leukemia: a SAKK trial.
Benz R; Arn K; Andres M; Pabst T; Baumann M; Novak U; Hitz F; Hess U; Zenhaeusern R; Chalandon Y; Mey U; Blum S; Rauch D; O'Meara Stern A; Cantoni N; Bargetzi M; Bianchi-Papina E; Rossi D; Passweg J; Lohri A; Berardi S; Li Q; Feller A; Stussi G
Blood Adv; 2020 Aug; 4(15):3699-3707. PubMed ID: 32777066
[TBL] [Abstract][Full Text] [Related]
27. The treatment of hairy cell leukemia with a focus on long lasting responses to cladribine: A 30-year experience.
Broccoli A; Argnani L; Nanni L; Terragna C; Sabattini E; Gabrielli G; Stefoni V; Pellegrini C; Casadei B; Morigi A; Lolli G; Carella M; Coppola PE; Zinzani PL
Am J Hematol; 2021 Oct; 96(10):1204-1210. PubMed ID: 34245477
[TBL] [Abstract][Full Text] [Related]
28. Hairy-cell leukaemia: first-line treatment with cladribine or pentostatin.
Prescrire Int; 2006 Aug; 15(84):143-4. PubMed ID: 16989031
[TBL] [Abstract][Full Text] [Related]
29. Long-term follow-up of cladribine treatment in hairy cell leukemia: 30-year experience in a multicentric Italian study.
Pagano L; Criscuolo M; Broccoli A; Piciocchi A; Varettoni M; Galli E; Anastasia A; Cantonetti M; Trentin L; Kovalchuk S; Orsucci L; Frustaci A; Spolzino A; Volpetti S; Annibali O; Storti S; Stelitano C; Marchesi F; Offidani M; Casadei B; Nizzoli ME; De Luca ML; Fianchi L; Motta M; Guarnera L; Simonetti E; Visentin A; Vassallo F; Deodato M; Sarlo C; Olivieri A; Falini B; Pulsoni A; Tiacci E; Zinzani PL
Blood Cancer J; 2022 Jul; 12(7):109. PubMed ID: 35853850
[TBL] [Abstract][Full Text] [Related]
30. The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia.
Else M; Osuji N; Forconi F; Dearden C; Del Giudice I; Matutes E; Wotherspoon A; Lauria F; Catovsky D
Cancer; 2007 Nov; 110(10):2240-7. PubMed ID: 17886250
[TBL] [Abstract][Full Text] [Related]
31. Long-term follow-up studies in hairy cell leukemia.
Grever MR; Zinzani PL
Leuk Lymphoma; 2009 Oct; 50 Suppl 1():23-6. PubMed ID: 19814694
[TBL] [Abstract][Full Text] [Related]
32. Multicenter retrospective analysis regarding the clinical manifestations and treatment results in patients with hairy cell leukemia: twenty-four year Turkish experience in cladribine therapy.
Hacioglu S; Bilen Y; Eser A; Sivgin S; Gurkan E; Yildirim R; Aydogdu I; Dogu MH; Yilmaz M; Kayikci O; Tombak A; Kuku I; Celebi H; Akay MO; Esen R; Korkmaz S; Keskin A
Hematol Oncol; 2015 Dec; 33(4):192-8. PubMed ID: 25393847
[TBL] [Abstract][Full Text] [Related]
33. Risk of additional cancers in untreated and treated hairy cell leukemia patients.
Dasanu CA; Alexandrescu DT
Expert Opin Pharmacother; 2010 Jan; 11(1):41-50. PubMed ID: 20001428
[TBL] [Abstract][Full Text] [Related]
34. A population-based study of hairy cell leukemia over a period of 20 years.
Wiber M; Maitre E; Poncet JM; Duchenet V; Damaj G; Cornet E; Troussard X
Cancer Treat Res Commun; 2020; 25():100236. PubMed ID: 33227559
[TBL] [Abstract][Full Text] [Related]
35. Characteristics and treatment patterns among US patients with hairy cell leukemia: a retrospective claims analysis.
Divino V; Karve S; Gaughan A; DeKoven M; Gao G; Knopf KB; Lanasa MC
J Comp Eff Res; 2017 Sep; 6(6):497-508. PubMed ID: 28485619
[TBL] [Abstract][Full Text] [Related]
36. Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up.
Hoffman MA; Janson D; Rose E; Rai KR
J Clin Oncol; 1997 Mar; 15(3):1138-42. PubMed ID: 9060556
[TBL] [Abstract][Full Text] [Related]
37. Cladribine in the treatment of hairy cell leukemia: initial and subsequent results.
Huynh E; Sigal D; Saven A
Leuk Lymphoma; 2009 Oct; 50 Suppl 1():12-7. PubMed ID: 19814692
[TBL] [Abstract][Full Text] [Related]
38. Long-term outcome of hairy cell leukemia treated with 2-chlorodeoxyadenosine.
Jehn U; Bartl R; Dietzfelbinger H; Vehling-Kaiser U; Wolf-Hornung B; Hill W; Heinemann V
Ann Hematol; 1999 Mar; 78(3):139-44. PubMed ID: 10211756
[TBL] [Abstract][Full Text] [Related]
39. Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series.
Rosenberg JD; Burian C; Waalen J; Saven A
Blood; 2014 Jan; 123(2):177-83. PubMed ID: 24192579
[TBL] [Abstract][Full Text] [Related]
40. Patients with relapsed/refractory hairy-cell leukemia.
Paillassa J; Troussard X
Cancer Rep (Hoboken); 2022 Mar; 5(3):e1495. PubMed ID: 34250762
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
